Fifty atherosclerotic patients with impaired glucose tolerance or type 2 DM underwent determination of blood chemistries , anthropometric and inflammatory variables , and FDG-PET/CT angiography , and then were randomized to receive either pioglitazone or glimepiride for 16 weeks .